1
Hendrik G Stunnenberg, Riccardo Wittek: Vaccinia DNA. Hoffmann La Roche, George M Gould, Bernard S Leon, William H Epstein, May 21, 1991: US05017487 (116 worldwide citation)

New transcriptional regulatory sequences useful in the expression of pro- or eukaryotic proteins in eukaryotic organisms are provided comprising the 5' flanking region of the vaccinia virus late 11 kDa gene. Also described are recombinant vectors and recombinant infectious poxviruses containing such ...


2
Stewart Shuman: Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. Sloan Kettering Institute for Cancer Research, John P White, June 16, 1998: US05766891 (72 worldwide citation)

This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a metho ...


3
Stewart Shuman: Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. Sloan Kettering Institute for Cancer Research, John P White, Cooper & Dunham, April 15, 2003: US06548277 (18 worldwide citation)

This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a metho ...


4

5
Stewart Shuman: Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. Sloan Kettering Institute for Cancer Research, John P White, Cooper & Dunham, June 23, 2009: US07550295 (2 worldwide citation)

This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a metho ...


6
Beaud Georges, Vassef Ahmad, Mars Mohamed, Dru Alfred: New vectors for cloning and expression in eukaryotic cells using the vaccinia virus. Centre Nat Rech Scient, April 4, 1986: FR2571060-A1 (2 worldwide citation)

The invention relates to a recombinant vaccinia virus which is useful as vector for cloning or expressing an exogene, characterised in that it comprises at least: all or part of the vaccinia virus genome; all or part of the EcoRI restriction fragment from ppBR322 inserted in the EcoRI site of the TK ...


7
Shuman Stewart: Method for molecular cloning and polynucleotide synthesis using vaccinia dna topoisomerase. Sloan Kettering Inst Cancer, April 8, 2009: EP2045259-A1 (1 worldwide citation)

This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a metho ...


8
Shuman Stewart: Method for molecular cloning and polynucleotide synthesis using vaccinia dna topoisomerase. Sloan Kettering Inst Cancer, March 18, 1998: EP0828755-A1 (1 worldwide citation)

This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a metho ...


9
Jan Zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse Van Rensberg, Thomas J Scriba: HIV-1 south african subtype C env proteins. Novartis Vaccines and Diagnostics, University of Stellenbosch, Morrison & Foester, March 21, 2017: US09598469

The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are ...


10
Harry B Demopoulos, Kevin Davis: Glutathione formulation and method of use. Molecular Defenses Corporation, Steven M Hoffberg, Tully Rinckey PLLC, February 27, 2018: US09901611

The use of glutathione to treat or prophylax viral, bacterial, chemical, and nuclear agents, or to treat or prophylax radiation injury to humans due to release of radioactive elements. The preferred formulation is an oral dosage form, with reduced glutathione stabilized by ascorbic acid, packaged to ...